Last $0.21 USD
Change Today -0.0029 / -1.40%
Volume 431.0
CRXM On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

taxus cardium pharmaceutical (CRXM) Snapshot

Open
$0.21
Previous Close
$0.21
Day High
$0.21
Day Low
$0.21
52 Week High
03/10/14 - $0.79
52 Week Low
02/13/15 - $0.07
Market Cap
2.5M
Average Volume 10 Days
16.8K
EPS TTM
$-0.45
Shares Outstanding
12.3M
EX-Date
10/24/05
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TAXUS CARDIUM PHARMACEUTICAL (CRXM)

Related News

No related news articles were found.

taxus cardium pharmaceutical (CRXM) Related Businessweek News

No Related Businessweek News Found

taxus cardium pharmaceutical (CRXM) Details

Taxus Cardium Pharmaceuticals Group Inc. operates as a development-stage regenerative medicine biotechnology company. It focuses on developing regenerative therapeutics designed to support the activation and growth of microvascular circulation to enhance perfusion of ischemic cardiac tissue as a potential treatment for heart disease; and granulation tissue as a treatment for chronic non-healing wounds. The company provides Excellagen, a topical gel for wound healing of diabetic foot ulcers, and other dermal wounds, as well as serves as a biologics delivery platform in the United States. It develops Generx, a lead Phase III clinical study product candidate for the treatment of patients with Cardiac Microvascular Insufficiency due to advanced coronary artery disease. In addition, the company develops LifeAgain, a medical analytics and social media-driven enabled e-commerce platform that is focused on developing, marketing, and direct sale of life insurance programs and other insurance products for individuals with prostate cancer. Taxus Cardium Pharmaceuticals Group Inc. has strategic collaborations with Shanxi Taxus Pharmaceuticals Co., Ltd. for the development of advanced regenerative medicine therapeutics products; and Orbsen Therapeutics Ltd. The company was formerly known as Cardium Therapeutics, Inc. and changed its name to Taxus Cardium Pharmaceuticals Group, Inc. in March 2014. Taxus Cardium Pharmaceuticals Group, Inc. was founded in 2003 and is headquartered in San Diego, California.

11 Employees
Last Reported Date: 04/15/14
Founded in 2003

taxus cardium pharmaceutical (CRXM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $332.8K
Co-Founder, Chief Business Officer, Executive...
Total Annual Compensation: $309.0K
Chairman of Scientific Advisory Board and Chi...
Total Annual Compensation: $244.3K
Compensation as of Fiscal Year 2013.

taxus cardium pharmaceutical (CRXM) Key Developments

TaxuCardium Pharmaceuticals Group Inc. Announces Election of New Directors

TaxuCardium Pharmaceuticals Group Inc. announced the election of the following three new directors Jiayue Zhang, president of Shanxi Taxus Pharmaceuticals Co. Ltd. (Shanxi Taxus) and Shenzhen Frontsea Taxus Industry Capital Management, John F. Wallace, president of Philadelphia Financial Services LLC and former chairman of the Philadelphia Stock Exchange, and Wei-Wei Zhang, as new members of the company's board of directors.

TaxuCardium Pharmaceuticals Group Inc. Reports Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2014

TaxuCardium Pharmaceuticals Group Inc. reported consolidated financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total product sales of nil compared with $19,200 a year ago. Loss from operations was $713,202 compared to $1,527,166 last year. Net loss was $1,441,802 compared to $1,769,005 last year. Net loss applicable to common stockholders was $1,441,802 or $0.12 per basic and diluted share compared to $1,941,866 or $0.28 per basic and diluted share last year. Non-GAAP net loss was $740,641 compared with $1,769,005 a year ago. Basic and diluted Non-GAAP net loss was $0.06 compared with $0.25 a year ago. For the nine months, the company reported product sales of nil compared with $109,200 a year ago. Loss from operations of $3,088,949 compared to loss from operations of $5,358,770 for the same period a year ago. Net loss was $3,865,216 compared to $6,148,908 last year. Net loss applicable to common stockholders was $3,865,216 or $0.36 per basic and diluted share compared to $6,554,780 or $0.99 per basic and diluted share last year. Non-GAAP net loss was $2,656,772 compared with $6,108,158 a year ago. Basic and diluted Non-GAAP net loss was $0.25 compared with $0.93 a year ago.

TaxuCardium Pharmaceuticals Group Inc. announced delayed 10-Q filing

On 11/17/2014, TaxuCardium Pharmaceuticals Group Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRXM:US $0.21 USD -0.0029

CRXM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CRXM.
View Industry Companies
 

Industry Analysis

CRXM

Industry Average

Valuation CRXM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAXUS CARDIUM PHARMACEUTICAL, please visit www.cardiumthx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.